| Eloxx Pharmaceuticals, Inc. |
10%+ Owner |
Common Stock |
616,592 |
$443,946 |
$0.7200 |
13 May 2021 |
By Pontifax Investment Fund |
| Keros Therapeutics, Inc. |
10%+ Owner |
Common Stock, $0.0001 par value per share |
5,250 |
$83,055 |
$15.82 |
15 Oct 2025 |
By Ran Nussbaum |
| Keros Therapeutics, Inc. |
10%+ Owner |
Common Stock, $0.0001 par value per share |
5,250 |
$83,055 |
$15.82 |
15 Oct 2025 |
By Tomer Kariv |
| Keros Therapeutics, Inc. |
10%+ Owner |
Common Stock, $0.0001 par value per share |
0 |
$0 |
$17.75 |
15 Oct 2025 |
By Pontifax (Cayman) IV, L.P. |
| Keros Therapeutics, Inc. |
10%+ Owner |
Common Stock, $0.0001 par value per share |
0 |
$0 |
$17.75 |
15 Oct 2025 |
By Pontifax (China) IV, L.P. |
| Keros Therapeutics, Inc. |
10%+ Owner |
Common Stock, $0.0001 par value per share |
0 |
$0 |
$17.75 |
15 Oct 2025 |
By Pontifax (Israel) IV, L.P. |
| Keros Therapeutics, Inc. |
10%+ Owner |
Common Stock, $0.0001 par value per share |
0 |
$0 |
$17.75 |
15 Oct 2025 |
By Pontifax Late Stage Fund, L.P. |
| LB PHARMACEUTICALS INC |
10%+ Owner |
Common Stock |
1,411,681 |
|
|
12 Sep 2025 |
Indirect |
| LB PHARMACEUTICALS INC |
10%+ Owner |
Series C Preferred Stock |
0 |
|
|
12 Sep 2025 |
Indirect |